• Vaccine Name: IDD-3
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007619
• Type: Dendritic cell
• Status: Clinical trial
• Preparation: The vaccine (IDD-3) consisted 8 doses of autologous monocyte-derived matured DC generated in serum-free medium with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin-13 (IL-13), pulsed with lysates of three allogeneic melanoma cell lines, and matured with interferon gamma (Ribas et al., 2010).
• Immunization Route: Intramuscular injection (i.m.)
• Description: The administration of matured DC loaded with tumor lysates has significant immunogenicity and antitumor activity in patients with limited metastatic melanoma (Ribas et al., 2010).

Baboon Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: (90%) had detectable TAA-specific CD8+ T cells in peripheral blood. 19/26 of patients with boosted/induced immune responses post-treatment to a single pool or multiple pools of TAA-derived peptides. 3/26 patients with stable immune response to one (or more) pool; and 4/26 patients with decreased immune response to one (or more) pool (Ribas et al., 2010).